You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昊海生物科技(06826.HK):預計首季淨利8000萬元至1億元 實現扭虧為盈
格隆匯 03-27 00:06

格隆匯 3 月 26日丨昊海生物科技(06826.HK)發佈公吿,與2020年同期相比,集團預計截至2021年3月31日止三個月將實現扭虧為盈。報吿期內,集團預計將實現未經審核歸屬於上市公司股東的淨利潤約人民幣8000萬元至人民幣1億元(2020年同期:未經審核歸屬於上市公司股東的淨虧損人民幣2485.54萬元);未經審核歸屬於上市公司股東扣除非經常性損益後的淨利潤預期約人民幣7500萬元至人民幣9500萬元(2020年同期:未經審核歸屬於上市公司股東扣除非經常性損益後的淨虧損人民幣3571.11萬元)。

公吿表示,報吿期錄得利潤較2020年同期增長並扭虧為盈的主要原因是隨着新冠肺炎疫情逐步得到控制,社會正常生產和生活恢復,以及集團持續積極進行各種類型的市場和營銷活動以維護集團產品市場份額,強化和加深市場對集團產品特別是新產品的認可度,使得報吿期內集團的銷售收入有較大的增幅。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account